Commercializing ideas for drug discovery and biological therapeutics
Commercializing ideas from physical and computer sciences, engineering, software, and services
Connecticut's strategic venture capital arm and the leading source of financing and ongoing support for innovative, growing companies.
The Yale Innovation Summit offers a premier opportunity to showcase your breakthrough technologies to a large number of interested investors and industry leaders, both through a prominent electronic poster display with interactive screens and through two live pitch events.
A brief application and a 5-minute (5-8 slide) PowerPoint deck is all you need to apply for either an electronic poster, the pitch contest, or both.
(Pitch Prizes will be awarded to the winning ventures.)
First Place $10,000
Second Place $5,000
Third Place $2,500
(ePoster Prizes will be awarded to the individual applicants.)
Highest Potential Impact $500
Most Innovative Solution $500
Best Poster Presentation $500
Additionally ten $250 prizes will be awarded to ten ePoster’s noted as
Promising Future New Haven Ventures.
We are seeking applicants from Yale Faculty for both the electronic posters and pitch contest. Consideration may be extended to alumni or community startups based on availability, but strong preference will be given to the founders with a current Yale affiliation spinning a technology out of Yale; Additionally, specifically regarding the pitch contest, strong preference will be given to faculty who have not previously been on stage at the Innovation Summit.
Submit your pitch deck and answer the application questions via the button below.
Your pitch deck should be non-confidential in PowerPoint and able to be pitched in 5 minutes. This PowerPoint pitch deck will also serve as the electronic poster that will be on display at the event. .
Incorporate the following elements for the most effective presentation:
- elevator pitch/company story
- management team/scientific advisory board
- market problem/unmet needs/commercial opportunity
- description of technology
- validation/supporting data
- product pipeline
- risk and risk mitigation
- differentiation from competitors
|March 31, 2020||Application Deadline|
|April 3, 2020||Pitch Semi-Finalists & E-Poster Selectees notified|
|April 7, 2020||Internal Pitchoff for Tech Pitch Semi-Finalists|
|April 8, 2020||Internal Pitchoff for Biotech Pitch Semi-Finalists|
|April 10, 2020||Pitch Finalists Notified|
|May 13, 2020||2020 Innovation Summit|
The National Cancer Institute (NCI) SBIR/STTR Development Center provides federal funding and resources to startups working on anti-cancer technologies including therapeutics, diagnostics, devices, radiation therapy and imaging, research tools, and digital health. The program’s budget has now grown to ~$180M a year, and we fund approximately 400 companies at any given time. Two NCI SBIR staff attended the 2020 Yale Innovation Summit, and they’re interested in meeting with Yale or small business staff who wish to pursue SBIR/STTR research funding. They can provide advice on how to prepare competitive funding applications.
Innovation programs at the National Science Foundation (NSF) advance ideas from the lab to the marketplace to strengthen America’s economy, health, and security. The Division of Industrial Innovation and Partnerships (IIP) in the Engineering Directorate leads several programs to translate fundamental research into market solutions. IIP supports researchers with promising technologies, as well as funding high-tech startups. Learn more about the NSF’s central role in accelerating the growth of the national ecosystem and hear about specific funding opportunities from an NSF employee at the 2020 Yale Innovation Summit.
Since its founding in 1992, Alexion has given hope to people who had none and shined a light on those who felt isolated and alone. But we know that fighting rare diseases takes so much more than hope. It requires persistence, dedication, and a relentless pursuit of the highest levels of medical innovation. At Alexion, our goal is to deliver medical breakthroughs where none currently exist. We are driven because we know people's lives are at stake. Alexion has 3,000 passionate and dedicated employees serving patients in 50 countries around the world.
For more information, contact Steve Meyers at firstname.lastname@example.org.
Arvinas is a clinical-stage biopharmaceutical company focused on developing new small molecules ‒ known as PROTAC® (PROteolysis Targeting Chimera) protein degraders ‒ aimed at degrading disease-causing cellular proteins via proteolysis. Based on innovative research conducted at Yale University by Dr. Craig Crews, Founder and Chief Scientific Advisor, the company is translating natural protein degradation approaches into novel drugs for the treatment of cancer and other diseases. Our proprietary PROTAC®-based drug paradigm induces protein degradation, rather than protein inhibition, using the ubiquitin proteasome system and offers the advantage of potentially targeting “undruggable” as well as “druggable” elements of the proteome. This greatly expands the ability to create drugs for many new, previously unapproachable targets.
For more information, contact Steve Weiss at email@example.com.
BioCT is the bioscience industry voice for the state of Connecticut. BioCT is dedicated to growing the vibrant bioscience ecosystem in Connecticut by supporting innovation, collaboration, networking, education, talent engagement and advocacy. We bring together companies, institutions, entrepreneurs, investors, government, service providers, and other passionate, dedicated people, to build a thriving community to improve patients’ lives and public health, while driving economic growth.
For more information, contact Kelley Gipson at firstname.lastname@example.org.
BioHaven is a clinical-stage biopharmaceutical company and their portfolio is comprised of innovative, late-stage product candidates targeting neurological and neuropsychiatric diseases, including rare disorders. In May 2019, they raised $168 million in IPO.
For more information, contact Kari Soderstrom at Kari.Soderstrom@biohavenpharma.com.
Boehringer Ingelheim is one of the world’s top 20 pharmaceutical companies. Headquartered in Ingelheim, Germany, the company operates globally with approximately 50,000 employees. Since its founding in 1885, the company has remained family-owned and today creates value through innovation for three business areas including human pharmaceuticals, animal health and biopharmaceutical contract manufacturing.
For more information, contact Sophia Salih at email@example.com.
Founded in 1929, the Jackson Laboratory is an independent, 501(c)3 nonprofit biomedical research institution. It employs more than 2,200 staff, and its mission is to discover precise genomic solutions for disease and empower the global biomedical community in the shared quest to improve human health. JAX researchers combine extensive experience in mammalian genetics and human genomics to shape a unique and integrated approach to personalized medicine. Scientists work collaboratively across disciplines to interrogate disease from all angles, leveraging diverse expertise in cancer, immunology (including diabetes), neurogenetics (including Alzheimer’s disease), life-cycle biology (including development, stem cells, aging and regenerative medicine), the microbiome and computational biology.
For more information, contact Miriam Ortiz at firstname.lastname@example.org.
Finding top talent is a key challenge for company executives in 2020. Yale's Office of Career Strategy (OCS) employer relations staff are available to help you build a recruiting strategy that will attract highly skilled Yale students across a diverse array of disciplines. Employers may post full-time and internship opportunities on Yale Career Link. Individual employers may host student engagement events on-campus, or remotely, and participate in one of 10+ industry networking events during the Fall and Spring terms.
For more information about recruiting options, please contact Employer Relations 203-432-0800.
Pfizer careers are like no other. In our culture of individual ownership, we believe in our ability to improve future healthcare, and potential to transform millions of lives. We’re looking for new talent to join our global community, to unearth new innovative therapies that make the world a healthier place.
For more information, contact Danielle Maciag at Danielle.Maciag@pfizer.com.
Thetis is a biopharmaceutical company developing potential first-in-class, non-immunosuppressive therapies for gastrointestinal inflammatory diseases. Founded by ex-Pfizer R&D executives and healthcare entrepreneurs, Thetis has a pipeline of drug candidates that offer a novel therapeutic approach to resolve inflammation without suppressing compromising immune function. Thetis is based in Branford, CT and is funded by Connecticut Innovations and leading research institutions, including National Institutes of Health, the Crohn’s and Colitis Foundation, and the Kenneth Rainin Foundation.
For more information, contact Aaron Mathias at email@example.com.
Room Block Name: Yale Innovation Summit
Rate: $187 plus tax
Call in Reservations: 1-800-THE-OMNI
Hotel Parking Parking: Self-park is $20 +tax and valet is $25 +tax.
***Shuttle Bus Service will be provided in the morning and evening to and from the Summit and Reception.
More details to come.***
Interested in Sponsorship?
Contact Tim Opstrup (Timothy.Opstrup@yale.edu) for sponsorship opportunities.
Annie Lamont and Moira Forbes opened the event with an informative conversation
Governor Ned Lamont Supports New Haven as a Preeminent Hub for Innovation and Entrepreneurism at the 2019 Yale Innovation Summit
Guests have several opportunities to network with over 1,000 Summit attendees, presenters, panelists and Keynotes
Panel Discussion on Breadth vs. Depth of Assets Platform in Value Creation
Promising Future New Haven Venture Winners
2019 Blavatnik Winners
2019 Pitch contest awards waiting to be presented.
The day ended with a lively reception where guests enjoyed cocktails and conversation